WindMIL Therapeutics and Cognate BioServices Announce Agreement to Expand MILs Manufacturing Capacity
10 mars 2020 07h00 HE
|
WindMIL Therapeutics; Cognate BioServices , Inc.
PHILADELPHIA, BALTIMORE, and MEMPHIS, Tenn., March 10, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer...
WindMIL Therapeutics Appoints Patrick Fabbio as Chief Financial Officer
05 mars 2020 07h00 HE
|
WindMIL Therapeutics
PHILADELPHIA and BALTIMORE, March 05, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today...
WindMIL Therapeutics and Providence Cancer Institute Announce Collaboration to Collect Bone Marrow from Patients with Breast Cancer to Develop Marrow-Infiltrating Lymphocytes (MILs™)
11 févr. 2020 07h00 HE
|
WindMIL Therapeutics
BALTIMORE and PHILADELPHIA and PORTLAND, Oregon, Feb. 11, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics (WindMIL) and Providence Cancer Institute (Providence) today announced that the first patient...
WindMIL Therapeutics Announces Cancer Immunotherapy Pre-Clinical Research Collaboration with University of Pennsylvania
05 févr. 2020 07h00 HE
|
WindMIL Therapeutics
BALTIMORE and PHILADELPHIA, Feb. 05, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today...
WindMIL Therapeutics Expands Leadership Team
07 janv. 2020 07h00 HE
|
WindMIL Therapeutics
BALTIMORE and PHILADELPHIA, Jan. 07, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today...
WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs™) in Combination with nivolumab (Opdivo®) for Treatment of Patients with Non-Small Cell Lung Cancer
19 déc. 2019 07h00 HE
|
WindMIL Therapeutics
BALTIMORE and PHILADELPHIA, Dec. 19, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics today announced it has entered into a new clinical research collaboration with Bristol-Myers Squibb Company...
WindMIL Therapeutics Announces Dosing of First Patient in a Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer
12 déc. 2019 07h00 HE
|
WindMIL Therapeutics
BALTIMORE and PHILADELPHIA, Dec. 12, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today...
WindMIL Therapeutics to Present Data Demonstrating Superior Efficacy of CAR-T cells using Marrow-Infiltrating Lymphocytes (CAR-MILs™) Compared to Peripheral Blood Lymphocytes at the 61st American Society of Hematology Annual Meeting and Exposition
09 déc. 2019 10h00 HE
|
WindMIL Therapeutics
BALTIMORE and PHILADELPHIA, Dec. 09, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, will present...
WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs™) Data Selected for Poster Presentation at 61st American Society of Hematology Annual Meeting and Exposition
06 nov. 2019 09h01 HE
|
WindMIL Therapeutics
BALTIMORE and PHILADELPHIA, Nov. 06, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, announced...
WindMIL Therapeutics to Present Data Demonstrating Marrow-Infiltrating Lymphocytes’ (MILs™) Superior Functionality Compared to Peripheral Blood Counterparts at 34th Annual Meeting of the Society for Immunotherapy of Cancer
05 nov. 2019 08h01 HE
|
WindMIL Therapeutics
BALTIMORE and PHILADELPHIA, Nov. 05, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, will present...